News

Hosted on MSN17d
CIRM awards $8m to Tr1X for trial of GvHD prevention drug candidate TRX103
The California Institute for Regenerative Medicine (CIRM) in California, US, has awarded an $8m grant to biotechnology company Tr1X to support its Phase I/IIa trial of TRX103, a drug designed to ...
Business Insider28d
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell ...
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of R&D at Tr1X, with patients enrolling at leading stem cell transplant centers across ...
The National Law Review20d
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell ...
manilatimes28d
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell ...